| News

Researchers in Basel develop dual-virus therapy for cancer

04.03.2021

Researchers at the University of Basel have developed a promising strategy for therapeutic cancer vaccines. They are expanding upon pre-existing vaccines to activate the immune system to fight off tumors using two viruses.

An international research group led by Professor Daniel Pinschewer from the Department of Biomedicine at the University of Basel has developed a new strategy for therapeutic cancer vaccines in animal trials. According to the press release from the university, this uses viruses that have been rendered harmless to transport cancer cells, which then activate the body’s immune system in such a way that it fights the tumor. Pinschewer’s therapy is innovative in its use of two viruses at staggered intervals instead of just one.

The press release explains that this method prevents the body’s innate immune system from attacking the viruses instead of the actual target, the “cargo” with cancer cells. By using two virus transporters one after the other, this effect was achieved in animal tests on mice. The immune system initially only uses killer T-cells to attack the cancer cells that have been introduced, and then attacks the tumor from which these were taken.

Pinschewer is quoted in the press release, saying: “By using two different viruses, one after the other, we focus the triggered immune response on the actual target, the tumor molecule. […] We can’t say anything about the efficacy of our approach in humans as yet […] However, since the therapy with two different viruses works better in mice than the therapy with only one virus, our research results make me optimistic.”

The Biotech company Hookipa Pharma in New York and Vienna, which Pinschewer co-founded, is now investigating the efficacy of this innovative approach to cancer therapy in humans in clinical trials. If the new approach is proven effective, the Basel researchers can also see it being used in combination with existing therapies in order to increase their efficacy.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

MTIP using new fund to invest in innovative companies
Basel Area Business & Innovation, Innovation, Invest

MTIP using new fund to invest in innovative companies

The Basel-based firm MTIP AG specializes in investments in HealthTech companies. A total of 130 million euros has already been...

Read More
Basel Area records successful 2020
Basel Area Business & Innovation, Innovation, Invest

Basel Area records successful 2020

Basel Area Business & Innovation was able to newly settle a total of 27 companies in the Basel Area in...

Read More
BetterDoc opts for Basel
Basel Area Business & Innovation, Innovation, Invest

BetterDoc opts for Basel

The online medical service BetterDoc has selected Basel as its Swiss location. Together with the health insurance firm Assura, it...

Read More
Kybora settles its European headquarters in Basel
Basel Area Business & Innovation, Innovation, Invest

Kybora settles its European headquarters in Basel

The American consultancy Kybora, which operates within the life sciences industry, has established its European headquarters in Basel. Kybora GmbH...

Read More
Escientia establishes subsidiary in the Basel Area
Basel Area Business & Innovation, Innovation, Invest

Escientia establishes subsidiary in the Basel Area

The U.S. company Escientia Life Sciences Group has established a subsidiary in the canton of Basel-Landschaft. Escientia Switzerland will offer...

Read More
Basel presents itself as center of innovation at the House of Switzerland in Tokyo
Basel Area Business & Innovation, Innovation, Switzerland Innovation Park

Basel presents itself as center of innovation at the House of Switzerland in Tokyo

Around a dozen innovative companies and institutions from the Basel Area are planning a joint marketing presence in Tokyo under...

Read More
1 2 3 11

Do you have a question? We'd like to hear from you.